<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208884">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368654</url>
  </required_header>
  <id_info>
    <org_study_id>200513613-1</org_study_id>
    <nct_id>NCT00368654</nct_id>
  </id_info>
  <brief_title>Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy</brief_title>
  <official_title>An Open-Label Study to Evaluate Whether a Short-Term Course of Methotrexate in Psoriasis Patients Treated With Efalizumab is Safe and Increases Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether a short-term course of methotrexate in patients treated with efalizumab
      (Raptiva) increases efficacy. The secondary objectives of this study are 1) to evaluate the
      efficacy of Raptiva in maintaining the clinical improvement induced by short-term treatment
      with combination therapy of Raptiva and methotrexate 2) to evaluate the safety of short-term
      combination therapy of Raptiva and methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate whether a short-term course of
      methotrexate in patients treated with efalizumab (Raptiva) increases efficacy. The secondary
      objectives of this study are 1) to evaluate the efficacy of Raptiva in maintaining the
      clinical improvement induced by short-term treatment with combination therapy of Raptiva and
      methotrexate 2) to evaluate the safety of short-term combination therapy of Raptiva and
      methotrexate.

      The design of this study is to gain better control of the disease process while reducing
      potential toxicities by beginning treatment with Raptiva and adding methotrexate to those
      patients who do not improve significantly
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI -- psoriasis area and severity index</measure>
    <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events, whether or not serious</measure>
    <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy with Raptiva alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with both Raptiva and Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue Raptiva, discontinue methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue combination therapy with both Raptiva and Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Initial dose 5 mg, then 15 mg per week</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva</intervention_name>
    <description>Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Efalizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe plaque-type psoriasis

          -  A candidate for systemic therapy or phototherapy

          -  Not using prescription systemic therapies for psoriasis prior to starting the study

          -  Not using efalizumab within 3 months prior to starting the study

        We are seeking adults who:

          -  Have moderate to severe plaque-type psoriasis

          -  Are generally healthy

          -  Are not hypersensitive to RaptivaÂ® (efalizumab) or any of its components.

          -  Are not pregnant or lactating women

        You will:

          -  Be interviewed and examined

          -  Have blood drawn

          -  Be injecting the study medication

        Exclusion Criteria:

          -  Hypersensitivity to Raptiva or any of its components

          -  Pregnant or lactating women

          -  History of liver disease or abnormal liver enzymes

          -  History of chronic infection or malignancy

          -  History of significant hematologic abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chai Sue Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center Department of Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 20, 2012</lastchanged_date>
  <firstreceived_date>August 24, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
